{"filing":{"accession_number":"0001213900-26-096692","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"ea0304456-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026096692/ea0304456-6k_clearmind.htm"},"events":[{"id":31275,"run_id":28690,"accession_number":"0001213900-26-096692","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This exhibit is a conversion agreement dated September 2, 2026, whereby Clearmind Medicine converts outstanding convertible notes totaling $696,079.50 into common shares at an agreed conversion price of $1.00 per share. The conversion results in issuance of approximately 696,079 common shares to accredited investors (L.I.A Pure Capital Ltd. and Capitalink Ltd.), which is dilutive to existing shareholders. The agreement explicitly waives the original conversion price formula in the notes and amends the floor price, indicating a negotiated restructuring of the debt-to-equity conversion that would materially affect share count and ownership structure.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-09-02","form":"6-K","submitted_at":null,"items":[{"id":34106,"accession_number":"0001213900-26-096692","item_number":"EX-99.1","item_title":"ea030445601ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This exhibit is a conversion agreement dated September 2, 2026, whereby Clearmind Medicine converts outstanding convertible notes totaling $696,079.50 into common shares at an agreed conversion price of $1.00 per share. The conversion results in issuance of approximately 696,079 common shares to accredited investors (L.I.A Pure Capital Ltd. and Capitalink Ltd.), which is dilutive to existing shareholders. The agreement explicitly waives the original conversion price formula in the notes and amends the floor price, indicating a negotiated restructuring of the debt-to-equity conversion that would materially affect share count and ownership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:04:58.767927+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34106,"accession_number":"0001213900-26-096692","item_number":"EX-99.1","item_title":"ea030445601ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This exhibit is a conversion agreement dated September 2, 2026, whereby Clearmind Medicine converts outstanding convertible notes totaling $696,079.50 into common shares at an agreed conversion price of $1.00 per share. The conversion results in issuance of approximately 696,079 common shares to accredited investors (L.I.A Pure Capital Ltd. and Capitalink Ltd.), which is dilutive to existing shareholders. The agreement explicitly waives the original conversion price formula in the notes and amends the floor price, indicating a negotiated restructuring of the debt-to-equity conversion that would materially affect share count and ownership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:04:58.767927+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-09-02"}]}